Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer
June 21 2022 - 4:50PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating novel, small molecule
drugs for viral infections and liver diseases, announced today that
it has filed suit in United States District Court for the District
of Massachusetts against Pfizer, Inc. seeking damages for
infringement of U.S. Patent No. 11,358,953 (the ’953 Patent) in the
manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™
(nirmatrelvir tablets; ritonavir tablets). The United States Patent
and Trademark Office awarded the patent to Enanta earlier this
month based on Enanta’s July 2020 patent application describing
coronavirus protease inhibitors invented by Enanta scientists. The
complaint can be accessed on Enanta’s website here.
Enanta recognizes the importance of Paxlovid’s availability to
patients and does not intend to seek an injunction or take other
action in this litigation that would impede the production, sale or
distribution of Paxlovid. Enanta seeks fair compensation for
Pfizer’s use of a coronavirus 3CL protease inhibitor claimed in the
‘953 patent.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
programs include clinical candidates currently in development for
the following disease targets: respiratory syncytial virus (RSV),
SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also
conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Enanta’s antiviral
clinical candidate for COVID-19 is a novel coronavirus 3CL protease
inhibitor, also known as a main protease inhibitor, or Mpro,
specifically designed as an oral treatment for COVID-19. Please
visit www.enanta.com for more information.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements,
including statements with respect to Enanta’s filing in the United
States District Court for the District of Massachusetts of a suit
against Pfizer, Inc. seeking damages for patent infringement and
Enanta’s intentions with respect to further action with respect to
such patent. Statements that are not historical facts are based on
management’s current expectations, estimates, forecasts and
projections about Enanta’s business and the industry in which it
operates and management’s beliefs and assumptions. The statements
contained in this release are not guarantees of future performance
and involve certain risks, uncertainties and assumptions, which are
difficult to predict. Therefore, actual outcomes and results may
differ materially from what is expressed in such forward-looking
statements. Important factors and risks that may affect actual
results include: Enanta is competing to develop intellectual
property in areas of small-molecule drug development that are
highly competitive; issued patents, including those covering one or
more of its product candidates, could be found invalid or
unenforceable if challenged in court and could be costly to defend
and be a distraction for Enanta’s senior management and scientific
personnel; intellectual property litigation may lead to unfavorable
publicity that harms Enanta’s reputation and causes the market
price of its common stock to decline; and other risk factors
described or referred to in “Risk Factors” in Enanta’s most recent
Form 10-Q for the fiscal quarter ended March 31, 2022 and other
periodic reports filed more recently with the Securities and
Exchange Commission. Enanta cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621006054/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024